Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis. - Wikidata - awgldk - TriplyDB

Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.

Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q35074335

about

Estrogen maintains myometrial tumors in a lymphangioleiomyomatosis model NK cell activating receptor ligand expression in lymphangioleiomyomatosis is associated with lung function decline Potential lymphangiogenesis therapies: Learning from current antiangiogenesis therapies-A review.

P2860

Q37193373-3F07B61E-2C27-49AD-93E6-23742C4252BA Q37316220-3BD76B92-375C-4FB2-869E-21A6FD4F0AD4 Q50419857-4908A7B8-7B0B-417E-BAA1-5ABD0D18DD02

P2860

Anti-EGFR antibody reduces lung nodules by inhibition of EGFR-pathway in a model of lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q35074335

description

2015 nî lūn-bûn

@nan

2015 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2015 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@ast

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@en

type

label

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@ast

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@en

prefLabel

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@ast

Anti-EGFR antibody reduces lun ...... l of lymphangioleiomyomatosis.

@en

P1433

Q35074335-3AB4FC48-D2EC-4D56-A2DF-6A0EECD30DA6

P1476

Q35074335-4C80EE4C-5DC2-4396-A636-9FAA95BA77B3

P2093

Q35074335-40F88DEB-781B-4B43-A3AE-12860986E3BC

Q35074335-7259AF1E-3C9B-4E99-AAC7-7067E1B4E4BB

Q35074335-AAB660D3-A292-4C53-BEFE-42CBCD40E416

P2860

Q35074335-07183241-832E-4FCA-83C8-F180248489B0

Q35074335-0CF79306-6083-44BE-B81B-9A9ED5391F30

Q35074335-10507030-B5C5-4E7D-9085-BB0731074C85

Q35074335-140D3D22-0279-484C-94D8-98527AD2FEC8

Q35074335-14A11974-D104-4CFD-86E4-64F2EB6E7289

Q35074335-17BF1A03-D215-437C-BF0A-1524F1E3E90E

Q35074335-254F8F7F-66F0-4746-BA24-0F06EE7C4499

Q35074335-332ADA3A-A62E-4597-B55C-E06BA813E2C4

Q35074335-36CF81B9-10A6-4935-9E8F-03EF6716C9CF

Q35074335-3CDF8246-664B-4D72-92FA-55E4A10FE020

P304

Q35074335-54A0E377-6528-48CB-A186-BCCD471C1D0C

P31

Q35074335-1D566C7F-03C2-47CD-B2BD-9F286738D5E0

P356

Q35074335-B03BDB4C-7A49-4FA0-8B72-DAFBC75E5CFB

P407

Q35074335-0767F08A-63F6-4D8C-85A3-95EE2C445D4E

P478

Q35074335-671F60A7-75EE-4907-BDE8-B560592FBE2E

P50

Q35074335-4AA0D5C2-A49A-43D9-A033-1327101DCA05

Q35074335-A94C8FC5-29B0-42C1-BAF4-DB0F3A0CCA40

Q35074335-E2CBA06E-77C1-4A6E-93EA-6D88D8991D6A

P577

Q35074335-767AD1C8-6349-4CC3-9E0A-DDB8526E872B

P5875

Q35074335-07D3544E-19C7-4517-8AF4-2AA1E22367A3

P698

Q35074335-76D08067-8ADD-4A09-8109-A806C8C3CBCB

P932

Q35074335-D6D1CF86-CDC9-4633-896B-60F36CE9FFBE

P356

P1433

BioMed Research International

P1476

Anti-EGFR antibody reduces lun ...... el of lymphangioleiomyomatosis

@en

P2093

Alfredo Gorio

http://www.w3.org/2001/XMLSchema#string

Emanuela Orpianesi

http://www.w3.org/2001/XMLSchema#string

Silvia Ancona

http://www.w3.org/2001/XMLSchema#string

P2860

Tuberous sclerosis complex-1 and -2 gene products function together to inhibit mammalian target of rapamycin (mTOR)-mediated downstream signaling

Efficacy and safety of sirolimus in lymphangioleiomyomatosis.

The basics of epithelial-mesenchymal transition

Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

Tuberin regulates E-cadherin localization: implications in epithelial-mesenchymal transition

Active PI3K pathway causes an invasive phenotype which can be reversed or promoted by blocking the pathway at divergent nodes

mTOR activation, lymphangiogenesis, and estrogen-mediated cell survival: the "perfect storm" of pro-metastatic factors in LAM pathogenesis

Target of rapamycin (TOR): an integrator of nutrient and growth factor signals and coordinator of cell growth and cell cycle progression

Cell size and invasion in TGF-beta-induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway

Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM)

P304

315240

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2015/315240

http://www.w3.org/2001/XMLSchema#string

P407

P478

2015

http://www.w3.org/2001/XMLSchema#string

P50

Anna Maria Di Giulio

Eloisa Chiaramonte

P577

2015-01-28T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272519265

http://www.w3.org/2001/XMLSchema#string

P698

25699271

http://www.w3.org/2001/XMLSchema#string

P932

4324894

http://www.w3.org/2001/XMLSchema#string